On 30 August 2011, orphan designation (EU/3/11/892) was granted by the European Commission to Repligen Europe Limited, Ireland, for 5-[1-(2,6-dichlorobenzyl)piperidin-4-ylmethoxy]quinazoline-2,4-diamine dihydrochloride for the treatment of 5q spinal muscular atrophy.
- What is 5q spinal muscular atrophy?
5q spinal muscular atrophy is an inherited disease that affects the motor neurons (nerves from the brain and spinal cord that control muscle movements). Patients with the disease lack a protein called ‘survival motor neuron’ (SMN) protein, which is essential for the normal functioning and survival of motor neurons. Without this protein, the motor neurons deteriorate and eventually die. This causes the muscles to fall into disuse, leading to muscle wasting (atrophy) and weakness. Muscle weakness is usually more severe in the proximal musculature (the muscles closest to the trunk). The disease is linked to a defect on chromosome 5q and is usually diagnosed in the first year of life.
5q spinal muscular atrophy disease is a long-term debilitating and life-threatening disease because it causes breathing problems and paralysis that worsens over time.
- What is the estimated number of patients affected by the condition?
At the time of designation, 5q spinal muscular atrophy affected approximately 0.2 in 10,000 people in the European Union (EU)*. This is equivalent to a total of around 10,000 people, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 27), Norway, Iceland and Liechtenstein. This represents a population of 506,300,000 (Eurostat 2011).
- What treatments are available?
At the time of designation, no satisfactory methods were authorised in the EU for the treatment of 5q spinal muscular atrophy. Patients received supportive treatment to help them and their families cope with the symptoms of the disease. This included chest physiotherapy and physical aids to support muscular function, and ventilators to help with breathing.
- How is this medicine expected to work?
Patients with 5q spinal muscular atrophy lack SMN genes of which there are two types, SMN1 and SMN2. Many patients lack SMN1 but have SMN2, which normally produces low levels of the SMN protein.
This medicine is expected to increase the level of SMN protein produced by SMN2, thereby increasing the survival of motor neurons. It is expected to do this by blocking DcpS (scavenger decapping enzyme), the enzyme that is responsible for the low protein yield through its action in cutting (splicing) messenger RNA (genetic material involved in protein synthesis).
- What is the stage of development of this medicine?
At the time of submission of the application for orphan designation, the evaluation of the effects of 5-[1-(2,6-dichlorobenzyl)piperidin-4-ylmethoxy]quinazoline-2,4-diamine dihydrochloride in experimental models was ongoing.
At the time of submission of the application for orphan designation, no clinical trials with the medicine in patients with 5q spinal muscular atrophy had been started.
At the time of submission, this medicine was not authorised anywhere in the EU for 5q spinal muscular atrophy. Orphan designation of this medicine had been granted in the United States of America for spinal muscular atrophy.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 10 June 2011 recommending the granting of this designation.
- Opinions on orphan medicinal product designations are based on the following three criteria:
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
|Name||Language||First published||Last updated|
|EU/3/11/892: Public summary of opinion on orphan designation: 5-[1-(2,6-dichlorobenzyl)piperidin-4-ylmethoxy]quinazoline-2,4-diamine dihydrochloride for the treatment of 5q spinal muscular atrophy||(English only)||21/09/2011|
|Active substance||5-[1-(2,6-Dichlorobenzyl)piperidin-4-ylmethoxy]quinazoline-2,4-diamine dihydrochloride|
|Disease/condition||Treatment of 5q spinal muscular atrophy|
|Date of decision||30/08/2011|
|Orphan decision number||EU/3/11/892|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor’s contact details:
Repligen Europe Limited
25/28 North Wall Quay
Republic of Ireland
Telephone: + 353 42 93 76 973
Telefax: + 353 42 93 76 740
For contact details of patients’ organisations whose activities are targeted at rare diseases see:
- Orphanet, a database containing information on rare diseases which includes a directory of patients’ organisations registered in Europe.
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.